Update on Locally Advanced Breast Cancer

Oncologist

Volumn 8, Issue 6, 2003, Pages 521-530

  Giordano, Sharon H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Inflammatory breast cancer; Locally advanced disease

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXANE DERIVATIVE;

BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER STAGING; CLINICAL TRIAL; EVALUATION; HUMAN; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR VOLUME;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERPROFESSIONAL RELATIONS; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT;

EID: 0345016016     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.8-6-521     Document Type: Review

References (105)

1. Singletary SE, Allred C, Ashley P et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-3636.
2. Cristofanilli M, Buzdar AU, Hortobágyi GN. Update on the management of inflammatory breast cancer. The Oncologist 2003;8:141-148.
3. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. SEER Program Public Use Data Tapes 1973-1998, November 2000 Submission. Issued: April 2001.
4. Seidman H, Gelb SK, Silverberg E et al. Survival experience in the Breast Cancer Detection Demonstration Project. CA Cancer J Clin 1987;37:258-290.
5. National Comprehensive Cancer Network. Practice Guidelines in Oncology. Breast. Version 2. 2002.
6. Toonkel LM, Fix I, Jacobson LH et al. Locally advanced breast carcinoma: results with combined regional therapy. Int J Radiat Oncol Biol Phys 1986;12:1583-1587.
7. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-187.
8. Valagussa P, Zambetti M, Bignami P et al. T3b-T4 breast cancer: factors affecting results in combined modality treatments. Clin Exp Metastasis 1983;1:191-202.
9. Stewart JF, King RJ, Winter PJ et al. Oestrogen receptors, clinical features and prognosis in stage III breast cancer. Eur J Cancer Clin Oncol 1982;18:1315-1320.
10. Bonnefoi H, Diebold-Berger S, Therasse P et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol 2003;14:406-413.
11. Ozmen V, Cabioglu N, Dolay K et al. Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome. Breast Cancer Res Treat 2001;68:147-157.
12. Silvestrini R, Daidone MG, Valagussa P et al. Cell kinetics as a prognostic marker in locally advanced breast cancer. Cancer Treat Rep 1987;71:375-379.
13. Haagensen C, Stout A. Carcinoma of the breast II - criteria of operability. Ann Surg 1943;118:1032-1051.
14. Baclesse F. Five-year results in 431 breast cancers treated solely by roentgen rays. Ann Surg 1965;161:103-104.
15. Fletcher GH, Montague ED. Radical irradiation of advanced breast cancer. Am J Roentgenol 1965;93:573-584.
16. Spanos WJ Jr, Montague ED, Fletcher GH. Late complications of radiation only for advanced breast cancer. Int J Radiat Oncol Biol Phys 1980;6:1473-1476.
17. De Lena M, Zucali R, Viganotti G et al. Combined chemotherapy radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978;1:53-59.
18. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-906.
19. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-942.
20. Grohn P, Heinonen E, Klefstrom P et al. Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. Cancer 1984;54:670-674.
21. Rubens RD, Bartelink H, Engelsman E et al. Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792). Eur J Cancer Clin Oncol 1989;25:667-678.
22. Derman DP, Browde S, Kessel IL et al. Adjuvant chemotherapy (CMF) for stage III breast cancer: a randomized trial. Int J Radiat Oncol Biol Phys 1989;17:257-261.
23. Swain SM, Sorace RA, Bagley CS et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987;47:3889-3894.
24. Hortobágyi GN, Blumenschein GR, Spanos W et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983;51:763-768.
25. Powles TJ, Hickish TF, Makris A et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995;13:547-552.
26. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685.
27. Semiglazov VF, Topuzov EE, Bavli JL et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 1994;5:591-595.
28. van der Hage JA, van de Velde CJ, Julien JP et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-4237.
29. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983.
30. Hutcheon AW, Heys SD, Miller ID et al. Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer: a randomised controlled trial [abstract]. Breast Cancer Res Treat 2001;69:300.
31. Nabholtz JM, Falkson C, Campos D et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21:968-975.
32. Sledge GW, Neuberg D, Bernardo P et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588-592.
33. de Matteis A, Nuzzo F, D'Aiuto G et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer 2002;94:895-901.
34. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [comment]. N Engl J Med 2001;344:783-792.
35. Burstein HJ, Harris LN, Gelman R et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003;21:46-53.
36. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
37. Green MC, Buzdar AU, Smith T et al. Weekly paclitaxel (P) followed by FAC as primary systeniic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3-week P therapy followed by FAC-final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 2002;21:135a.
38. Therasse P, Mauriac L, Welnicka-Jaskiewicz M et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003;21:843-850.
39. Baldini E, Gardin G, Giannessi PG et al. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol 2003;14:227-232.
40. Perloff M, Lesnick GJ, Korzun A et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol 1988;6:261-269.
41. Hortobágyi GN, Ames FC, Buzdar AU et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988;62:2507-2516.
42. Bonadonna G, Veronesi U, Brambilla C et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990;82:1539-1545.
43. Jacquillat C, Baillet F, Weil M et al. Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy, and external and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA-IIIB). Cancer 1988;61:1977-1982.
44. Pierce LJ, Lippman M, Ben-Baruch N et al. The effect of systemic therapy on local-regional control in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 1992;23:949-960.
45. Schwartz GF, Birchansky CA, Komarnicky LT et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994;73:362-369.
46. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493.
47. Kuerer HM, Newman LA, Buzdar AU et al. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am 1998;4:230-236.
48. Esserman L, Kaplan E, Partridge S et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 2001;8:549-559.
49. Abraham DC, Jones RC, Jones SE et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 1996;78:91-100.
50. Davis PL, Staiger MJ, Harris KB et al. Breast cancer measurements with magnetic resonance imaging, ultrasonography, and mammography. Breast Cancer Res Treat 1996;37:1-9.
51. Rieber A, Zeitler H, Rosenthal H et al. MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol 1997;70:452-458.
52. Feldman LD, Hortobágyi GN, Buzdar AU et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986;46:2578-2581.
53. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-469.
54. Abu-Farsakh H, Sneige N, Atkinson EN et al. Pathologic predictors of tumor response to preoperative chemotherapy in locally advanced breast carcinoma. Breast J 1995;1:96-101.
55. Resnick JM, Sneige N, Kemp BL et al. p53 and c-erbB-2 expression and response to preoperative chemotherapy in locally advanced breast cancer. Breast Dis 1995;8:149-158.
56. Stearns V, Singh B, Tsangaris T et al. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 2003;9:124-133.
57. Coon JS, Marcus E, Gupta-Burt S et al. Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002;8:1061-1067.
58. Park K, Kim J, Lim S et al. Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 2003;39:631-634.
59. Anelli A, Brentani RR, Gadelha AP et al. Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer. Ann Oncol 2003;14:428-432.
60. Geisler S, Lonning PE, Aas T et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505-2512.
61. Formenti SC, Spicer D, Skinner K et al. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 2002;52:397-405.
62. Pusztai L, Ayers M, Simmans FW et al. Emerging science: prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. Proc Am Soc Clin Oncol 2003;22:1a.
63. Singletary SE, McNeese MD, Hortobágyi GN. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 1992;69:2849-2852.
64. Kuerer HM, Singletary SE, Buzdar AU et al. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg 2001;182:601-608.
65. Calais G, Descamps P, Chapet S et al. Primary chemotherapy and radiosurgical breast-conserving treatment for patients with locally advanced operable breast cancers. Int J Radiat Oncol Biol Phys 1993;26:37-42.
66. Olson J, Gray R, Sponzo R et al. Primary chemotherapy for nonresectable locally advanced breast cancer: 8 year results of an ECOG trial. Breast Cancer Res Treat 1990;16:148a.
67. Hortobágyi G, Singletary SE, Strom EA. Treatment of locally advanced and inflammatory breast cancer. In: Harris J, ed. Diseases of the Breast. Philadelphia: Lippincott Williams & Wilkins, 2000:645-660.
68. van Golen KL, Davies S, Wu ZF et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999;5:2511-2519.
69. McCarthy NJ, Yang X, Linnoila IR et al. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 2002;8:3857-3862.
70. Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2000;2:423-429.
71. Jaiyesimi IA, Buzdar AU, Hortobágyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992;10:1014-1024.
72. Paradiso A, Tommasi S, Brandi M et al. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer 1989;64:1922-1927.
73. Aziz SA, Pervez S, Khan S et al. Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J 2001;7:398-404.
74. Chevallier B, Asselain B, Kunlin A et al. Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis. Cancer 1987;60:897-902.
75. Palangie T, Mosseri V, Mihura J et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 1994;7:921-927.
76. Delarue JC, May-Levin F, Mouriesse H et al. Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast. Br J Cancer 1981;44:911-916.
77. Riou G, Le MG, Travagli JP et al. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst 1993;85:1765-1767.
78. Lee B, Tannenbaum N. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of Memorial Hospital. Surg Gynecol Obstet 1924;39:580-595.
79. Taylor G, Meltzer A. Inflammatory carcinoma of the breast. Am J Cancer 1938;33:33-49.
80. Haagensen C. Diseases of the Breast. Philadelphia: W. B. Saunders Co., 1956:488-498.
81. Donegan WL. Staging and end results. In: Donegan WL, ed. Cancer of the Breast. Philadelphia: Saunders, 1967:117-161.
82. Byrd BF, Stephenson SE Jr. Management of inflammatory breast cancer. South Med J 1960;53:945-948.
83. Rogers C, Fitts WT Jr. Inflammatory carcinoma of the breast. Surgery 1956;39:367-370.
84. Wang C, Griscom NT. Inflammatory carcinoma of the breast: results following orthovoltage and supervoltage radiation therapy. Clin Radiol 1964;15:168-174.
85. Haagensen C. Diseases of the Breast. Philadelphia: Saunders, 1971:576-584.
86. Blumenschein G, Montague ED, Eckles NE et al. Sequential combined modality therapy for inflammatory breast cancer. Breast 1976;2:16-20.
87. Ueno NT, Buzdar AU, Singletary SE et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997;40:321-329.
88. Attia-Sobol J, Ferriere JP, Cure H et al. Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis. Eur J Cancer 1993;29A:1081-1088.
89. Chevallier B, Bastit P, Graic Y et al. The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer 1993;67:594-601.
90. Thomas F, Arriagada R, Spielmann M et al. Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. Cancer 1995;76:2286-2290.
91. Arthur DW, Schmidt-Ullrich RK, Friedman RB et al. Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation. Int J Radiat Oncol Biol Phys 1999;44:289-296.
92. Zylberberg B, Salat-Baroux J, Ravina JH et al. Initial chemoimmunotherapy in inflammatory carcinoma of the breast. Cancer 1982;49:1537-1543.
93. Brun B, Otmezguine Y, Feuilhade F et al. Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation. Cancer 1988;61:1096-1103.
94. Thoms WW Jr, McNeese MD, Fletcher GH et al. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 1989;17:739-745.
95. Swain SM, Lippman ME. Treatment of patients with inflammatory breast cancer. Important Adv Oncol 1989:129-150.
96. Maloisel F, Dufour P, Bergerat JP et al. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer 1990;65:851-855.
97. Arriagada R, Mouriesse H, Spielmann M et al. Alternating radiotherapy and chemotherapy in non-metastatic inflammatory breast cancer. Int J Radiat Oncol Biol Phys 1990;19:1207-1210.
98. Buzdar AU, Singletary SE, Booser DJ et al. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am 1995;4:715-734.
99. Arun B, Slack R, Gehan E et al. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer 1999;85:93-99.
100. De Boer RH, Allum WH, Ebbs SR et al. Multimodality therapy in inflammatory breast cancer: is there a place for surgery? Ann Oncol 2000;11:1147-1153.
101. Hagelberg RS, Jolly PC, Anderson RP. Role of surgery in the treatment of inflammatory breast carcinoma. Am J Surg 1984;148:125-131.
102. Curcio LD, Rupp E, Williams WL et al. Beyond palliative mastectomy in inflammatory breast cancer-a reassessment of margin status. Ann Surg Oncol 1999;6:249-254.
103. Fleming RY, Asmar L, Buzdar AU et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol 1997;4:452-461.
104. Stearns V, Ewing CA, Slack R et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002;9:235-242.
105. van Golen KL, Bao L, DiVito MM et al. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther 2002;1:575-583.